List of Vendor Companies in China - 76

AlphaMa is a pioneering drug R&D company based in Suzhou, China, established in 2018. With artificial intelligence (AI) as the driving technology, DNA-encoded library (DEL) technology is cross-applied to establish a cutting-edge Intelligent DEL (iDEL) platform(including the first-class technology of on-demand DEL synthesis, DEL screening, hit confirmation, macrocyclic peptide DELs, customized glue library, etc.). The iDEL platform at AlphaMa features first-class DNA-encoded library (DEL) technology specializing in small molecule, macrocyclic peptide and covalent hit discovery, etc. With its mature screening technology and high success rate, providing global partners with a cost-effective and efficient one-stop DEL screening service. Our flexible service model, diversified services and excellent service system cover all stages of early drug discovery. We provide flexible and cost-effective approaches to meet customers' diverse needs with professional technology and high-quality services. AlphaMa is your ideal partner for drug discovery, assisting you in accelerating the drug discovery process. Reach out to learn more: liuyulin@aiphama.cn

Amoy Diagnostics (AmoyDx) is a visionary diagnostic company dedicated to transforming the landscape of cancer care. 'Breaking Barriers to Precision Oncology' reflects our commitment to revolutionizing cancer diagnosis and treatment. We are driven by four fundamental values: Innovation in Care, Accessibility and Equity, Collaboration and Partnership, and Integrity and Trust. These values guide our pursuit of developing groundbreaking diagnostic tools and fostering a more equitable, collaborative, and trustworthy approach to oncology. Join us as we pave the way to a future where precision cancer care is a reality for every patient, everywhere.

Zhifei is a high-tech biological enterprise integrating the R&D, production, distribution as well as import & export to mainly produce vaccines for human use.

Anpac Bio-Medical Science Company, Ltd., is led by award-winning and internationally respected biomedical and nanotechnology scientists, research and medical professionals, engineering experts and physicists -- creating and launching break-through, leading edge, early cancer and other disease screening, detection, and diagnostic technology. Anpac Bio's "Cancer Differentiation Analysis"​ (CDA) liquid biopsy technology incorporates proprietary, in-vivo (or non-invasive) screening and diagnostics devices that measure simple, "Blood Biopsies" -- assessing multiple microscopic parameters in whole blood samples, often identifying cancer pre-Stage One. Comprehensive research validity data from over 80,000 cases to date indicate Anpac's CDA screening and diagnostics far exceed existing or competing disease screening technologies - revealing a consistent sensitivity and specificity rate range of 70%-95% for over 26 different types of cancer to date. And it does so without any harmful side effects in patients; generating far fewer "false positives"; and at a cost substantially lower than traditional testing (such as imaging). Anpac Bio-Medical is an international company promoting a corporate culture of creativity, teamwork, balance, and commitment to excellence, family, and social responsibility. For more information regarding Anpac Bio-Medical Science Company, please check: www.AnpacBio.com.

The company specializes in the development of genetic testing programs, medical testing reagents and bioinformatics data analysis management software.

On August 20, 2024, Base Therapeutics announced that its AccuBase® base editor has officially received authorization for two patents from the United States Patent and Trademark Office (USPTO). This marks that both of Base Therapeutics' AccuBase® technologies have secured patent protection in China and overseas markets. Base Therapeutics' strategic positioning in the gene editing field is at the forefront internationally, making it one of the biopharmaceutical companies with the most authorizations domestically and abroad.

Beijing Challen Biotechnology Co., Ltd., located in Zhongguancun Science and Technology Park Biological Pharmaceutical Industry Base, Daxing District, Beijing, is a technology company specializing in the R&D, production and sales of biomedical technology products. Challen Biotechnology is committed to providing users with excellent one-stop services of flow cytometry (FCM), instruments and reagents. At present, its products mainly cover LongCyte™ and FongCyte™ FCM series, as well as auxiliary diagnostic reagent and automatic sample preparation instruments. There are nearly 300 users in China. Challen Biotechnology also provides solutions for clinical diagnosis, biotherapy, basic biomedical research, drug R&D, environmental materials, food toxicity monitoring, etc.

China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group's revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM's revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA.

Kewei's products include the diagnostic kits of hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B 'e' antigen, hepatitis B 'e' antibody and hepatitis B core antibody, hepatitis a virus IgM diagnostic kits, hepatitis E virus IgM diagnostic kits, RPR diagnostic kits, HBV test cassettes, HIV Ag/Ab diagnostic kits, etc.

Bio Bench co. ltd (www.bio-bench.com, Belgium and China) is aCRO (Contract Research Organization) that develops functionalantibodiesand bio-active proteins for drug discovery, in-vitro diagnostickits and biologicalresearch.

Biomarker Technologies provides high-throughput sequencing and bioinformatics services in areas of genomics, transcriptomics, epigenomics, population genomics, etc. They own all types of third-generation sequencing platformsincluding PacBio Sequel II, Sequel, RSII and Nanopore MinION, GridION and PromethION P48 as well as NGS platforms Illumina, DNBSEQ, etc.

BioTeke Corporation is a provider of molecular diagnostics instrument & related reagents. built at 2005, headquarter locates in Beijing, and factory in Wuxi city. We offer kinds of lab instruments as: Automated nucleic acid extraction system; UV-Vis spectrophotometer; 96 Gradient PCR; Centrifuge; Tip Rack Refill system; Automated liquid handling system; Gel imaging system And we also provide more than 100 kinds of DNA/RNA/Protein extraction reagents. Bioteke holds the philosophy to offer quick molecular diagnostic products with low price,high quality and superior services to the world.

Our company was Founded in 2007, Minnesota Bioworld Biotech., a company (Bioworld) is a private enterprise. We are committed to providing customers with innovative research tools, used to help determine the mechanisms of cell function and disease. Company since its establishment, has become the Bioworld antibody of cellular signal transduction pathways of the world's leading manufacturers. We are the world research, diagnosis and treatment to provide quality products, to contribute the biological world.

BoKu Biotech is an industrial micro-biotechnology company that focuses on the industrial microorganisms to replace traditional surfactants.

Established in 2012, BravoVax is located at BravoVax Building, 858 Gaoxin Avenue in the state-level biopharma development zone, Donghu hi-tech park of Wuhan, China. Relying on the experienced management team and international channels from parent company BravoBio and strong support from Humanwell Healthcare Group, one of the top 20 Chinese pharmaceuticals, we have kept the momentum in its development, maintaining fast growth. We are committed to the research and development of human vaccines and other biological products. The new pilot facility and R&D center are built at Wuhan biopharaceutical industrial park as per cGMP. All staffs hold a college and above degree, and more than 30% of them have master and above degrees as well as senior professional titles.

About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of： 1) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively. 2) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology. 燃石医学（纳斯达克代码：BNR）成立于2014年，公司使命为“用科学守护生命之光”，专注于为肿瘤精准医疗提供具有临床价值的二代基因测序（NGS）。公司业务及研发方向主要覆盖： 1）基于NGS的肿瘤患病人群检测，累计检测样本超过27万例，在中国拥有领先的市场份额； 2）基于NGS的癌症早检，目前已经进入临床验证阶段。 燃石医学于2018年7月获国家药品监督管理局（NMPA）颁发的中国肿瘤NGS检测试剂盒第一证，在体外诊断领域具有里程碑式意义。位于中国广州的实验室通过广东省临检中心颁发的“高通量测序实验室”技术审核，获得美国CLIA和CAP实验室质量体系资质认证；位于美国加利福尼亚州的实验室也已获得CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品，推动肿瘤精准医疗领域的发展。

who are we : Chempartner is an innovative company adhering to the principle of "Science First, Technology Leads," providing integrated services for pharmaceutical research and production (CRO+CDMO). It has developed advanced technological capabilities, assembled top-tier scientists, and equipped itself with state-of-the-art research, animal testing, and pharmaceutical intermediate production facilities. Vision Statement： We strive to ensure that all drugs can be produced and every disease can be addressed by creating an open-access platform equipped with the most advanced capabilities and technologies in the global pharmaceutical sector. Mission Statement Our goal is to revolutionize and expedite the discovery, development, and manufacturing of pharmaceuticals. By providing a comprehensive open-access platform, we empower our global healthcare partners and improve patient outcomes around the world. Our PROUD Culture Passion: Committed to customer satisfaction, continuous innovation, and a vibrant, energetic workplace. Responsibility: Embracing accountability, handling challenging tasks with integrity, and contributing to the community. Open Culture: Promoting teamwork, diversity, inclusion, and transparent communication. R&D Focus: Prioritizing research and development, advancing scientific excellence, and fostering innovation.

Chongqing Sintaho Pharmaceutical Co., Ltd. takes chemistry as the core, located at Chongqing International Biological City in China, jointly founded by Chongqing Taihao Pharmaceutical Co., Ltd. (established in 2004) and a US new-drug enterprise in July 2016. With 260+ employees integrated with R&D, production, regulatory affairs, and marketing, Sintaho commits itself to the global market, particularly the US, EU, and China. Sintaho specializes in chemosynthetic APIs (therapeutic areas mainly contain oncology, nervous system and metabolic diseases), with a product portfolio ranging from small molecule APIs, ADC compounds (linkers and payloads) to polypeptides, also provides CDMO services of cytotoxic and OEB4/5 grade APIs. Sintaho contributes to being the most dependable partner for global pharmaceutical companies.

Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and biotherapy. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics. Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in 68 countries and regions, serving more than 2,500 business partners worldwide.

复旦大学，简称复旦，始建于1905年，初名复旦公学，是中国人自主创办的第一所高等学校，创始人为中国近代知名教育家马相伯，首任校董为国父孙中山先生。"复旦"二字选自《尚书大传·虞夏传》中"日月光华，旦复旦兮"的名句，意在自强不息，寄托当时中国知识分子自主办学、教育强国的希望。 复旦大学是教育部与上海市共建的首批全国重点大学，中国首批7所211工程、9所985工程大学，首批"珠峰计划"、"111计划"和中国顶尖学府"九校联盟"（C9联盟）的成员大学。

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China.

Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.

普瑞盛（北京）医药科技开发有限公司（GCP ClinPlus Co.，Ltd.），简称普瑞盛，是中国顶尖的医药产品临床研究服务提供商。经过十六年的发展，逐步融合发展成为今天中国规模和综合实力均名列前茅的，既能够提供本土服务，又能直接提供境外跨国服务的综合临床研究服务公司。 普瑞盛拥有200多名全职员工，覆盖北京、上海、广州、南京、长沙、武汉、成都、西安、沈阳、天津、太原、石家庄、哈尔滨、新疆等10多个城市，并在美国建立了分公司。 普瑞盛致力于提供全方位的、符合国际标准的、充分利用人脉和地域资源的精准临床研究服务方案。 • CRO领域已参与1000+项临床研究（200+项全方位的临床服务） • 中国领先的数据统计团队 • 丰富的大型药物临床试验操作经验 • 专业的医疗器械临床研究服务团队 • 全方位的医学支持团队 • 丰富的CFDA答辩经验 团队朝气蓬勃，经验丰富，专业功底深厚。经过行业内十多年的积累，普瑞盛得到了众多知名企业的认可，目前客户遍布国内外排名前20的药企和医疗器械企业。

Genetron Holdings Limited ("Genetron Health" or the "Company") is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.

3/28/24- the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company. Genetron Holdings Limited (“Genetron Health” or the “Company”) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.

Founded in 1992 and listed in 2015, Wondfo is a fast-growing biotechnology company in China. Wondfo mainly focuses on rapid diagnostics in China but is looking for further development in other areas of the healthcare industry. Besides the headquarter in Guangzhou, Wondfo also owns 2 overseas labs, 1 branch in Chicago, and 11 overseas offices. After many years’ efforts in delivering high-quality products and services, Wondfo has won a good reputation around the world. In production, Wondfo strictly complies with national and international regulations and standards. We have got CE certificates, FDA certificates, FSC certificates, ISO 9001:2008, and ISO 13485:2012 quality system certification. Wondfo attaches great importance to research and development and sees innovation as the soul of the enterprise’s development. So far, Wondfo has 530+ highly-qualified researchers and over 30% of the staff have obtained master's and doctorate degrees from prestigious universities worldwide. Wondfo also has built R&D laboratories in Guangzhou and San Diego. With our advanced production lines and highly experienced staff, Wondfo’s daily production capacity of test kits reaches 1.5 million. Wondfo also provides a number of customized services to professional distributors and partnering affiliates. Wondfo provides high-quality products at a very competitive price, together with professional technical support and counseling service. Currently, Wondfo has customers in more than 120 countries and areas. It is our commitment to safeguarding the health and improving lives with better products, services, and solutions. With more than 3000 dedicated employees, we'll continue to innovate and shape the future of POCT and healthcare.

Establish in 2008 in China Hangzhou city, Biotest is mainly engaged in the R&D, production and sales of in vitro diagnostic reagents, divided into 5 catagories: drug abuse testing, infectious desease testing, fertility health, tumor marker testing and cardiology market testing. E-mail: info-B@biotests.com.cn Nous sommes spécialisés dans la R&D, la production et la commercialisation des réactifs de laboratoire, surtout des tests de dépistage rapide depuis 14 ans et nous travaillons avec plus de 500 professionnels dans le domaine médical. Nous attachons une grande impportance à la qualité et la prise en charge du client. Contactez le +86 571 8905 8143 pour plus d'information.

Founded in 2015 with the pursuit for human and global health,Testsealabs Inc.creates innovative tech-nologies for the development of raw materials for diagnostic use.We offer diagnostic total solution such as rapid diaqnostic tests(RDTs),fluorescent immuno-diaqnostic tests, ELISA,molecular diagnostic tests(MDx)and clinical chemistry. We specialize in developing monoclonal antibodies and recombinant antigens in-house at our facility in China.We also have patented technoloqies includingfluorescentimmuno-diagnostics which will be one of the major IVD technologies of the future. Our facility is GMP,ISO9001and ISO13458 certified and we have CE FDA approval. Now we are looking forward to cooperating with more overseas companies for mutual development. Since its establishment,Testsealabs Inc has always insisted on R&D and innovation. At present, it has accumulated 1 software copyright and 50 authorized patents, including 4 invention patents, 46 new patents for use, and several special projects under application. Testsealabs Inc currently has more than 300 employees, an annual output of 300 million people, and a business area of 56,000 square meters. We pursuing the concept of "integrity, quality and responsibility", adhering to the tenet of quality first and serving the society, we constantly strive to develop new high-quality diagnostic raw materials, always adhere to the vision of serving the society and a healthy world, and are committed to promoting high-quality diagnostic products. Accurate diagnosis of all human diseases contributes to the cause of human health. Always find us here for solutions!

Founded in 2014, HaploX aims to integrate liquid biopsy technology, gene sequencing, artificial intelligence, big data, and other technologies to improve the management of cancer patients. HaploX's technologies include tools for capturing circulating tumor DNA; extracting and amplifying ultra-low concentrations of DNA from liquid samples; performing tagged sequencing; and managing and analyzing the resulting data. Presently, HaploX's polycentric global distribution include: Shenzhen R & D Headquarter, Third-party Medical Laboratory, GMP Factory, US R & D center and ShangRao International Precision Medical Health Industrial Park. HaploX obtained a certificate of participation from EMQN(The European Molecular Genetics Quality Network) in 2017 and achieved both satisfactory results in two external quality assessment schemes: Lung Cancer(NSCLC)2 and Oncogene panel testing. HaploX possesses the most advanced platforms in the world: Illumina's NextSeqs, HiSeq X Tens, NovaSeq 6000 series and digital PCR. HaploX's throughput is now the second in the world rankings. In December 28th, 2017, HaploX Biotechnology raised $32 million in series A+ round. At the same time, NIVIDA accepted HaploX as a member in Inception program(a program started by NIVIDA in order to support startups that are revolutionizing industries with advances in artificial Intelligence and data science). The firm will continue to develop its sequencing technology, which is capable of detecting circulating tumor DNA for personalized cancer therapy.

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services. As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide.

Gene fragment analysis applications

Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. These three synergistic business segments are driven by the mission of addressing patients' unmet medical needs and bringing safe and effective therapies and services to patients around the world.

HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com

SHENTEK is a premier brand dedicated to providing high-quality QC solutions to the biopharmaceutical industry. Our standardized and customized quality control (QC) products cater to various cell species and manufacturing processes. We have successfully supported thousands of customers from R&D stage to product release, including pre-IND, IND and BLA filing. Whether you require ready-made products or tailored solutions, SHENTEK is your trusted partner for your quality control needs.

ICE Bioscience was founded in 2010 as an Innovative CRO+ Explorer company. We specialize in early drug discovery services, spanning from target validation to the identification of pre-clinical candidates. Currently, ICE Bioscience offers a broad selection of off-the-shelf assays, including 100+ ion channels, 800+ Kinases/enzymes, 100+ GPCRs, and 40+ nuclear receptor assays, all accompanied by validation data and screening information. This comprehensive range of assays provides us with a competitive edge, as it covers a vast majority of druggable targets. Our company has established multiple platforms, encompassing Protein Engineering, Cell Line Development, Target Based Assays, Safety Pharmacology, Translational Biology, DMPK, In Vivo Pharmacology and Biophysical Assays, enabling us to smoothly execute the DMTA cycle (Design-Make-Test-Analysis cycle) for innovative drug discovery in collaboration with our clients.

Innovax delivers superior, long-term disease protection against infectious poultry diseases. Through rigorous research and development, it develops new ways to optimize flock protection and increase production efficiency with breakthrough vaccinations.

KMD Bioscience is a biotech company located in Tianjin, China. Our CRO services&products cover antibody engineering(recombinant antibodyproduction, antibody sequencing&purification), protein production, expressionand purification and other services related to phage display, stable cell lineconstructionand peptide.

Landwind Medical has been a professional medical equipment manufacturing company since 1994. With over 25 years of experience in the medical industry, today, Landwind has six R&D centers and four production lines around China, besides Shenzhen's headquarters. Also, Landwind has perceptive R&D teams of 300+ professionals with medical practice and product development backgrounds. Landwind Group has four subsidiaries manufacturing different categories of medical products: Landwind Bio: for in-vitro diagnostic equipment and reagent solutions; Joyheal: for hemodialysis solutions; Landsky: is a specialist in ventilator & anesthesia solutions; Landwind Health: for home care/medical solutions. Professionally, Landwind is accumulating, gaining many professional awards and certificates every year, among them the CE, ISO9001, and CMD certificates, besides hundreds of local awards, Medical Device Manufacturing certificates, and patents. Landwind's products and professional staff are always on the front line with medical companies in most medical exhalation and fairs early, aiming to expand its cooperation network and open new markets. Landwind Medical's distributing network exceeds 800 and has more than 120,000 active clients covering more than 150 countries.

LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) is a translational medicine service provider with 10 years of delivering innovations in oncology translational research and immuno oncology. Founded in 2011 by overseas returnees Drs. Danyi Wen, Yizhun Zhu, et al, LIDE brings together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. We operate at the forefront of new technologies and adopt the highest international accreditation standards. LIDE offers traditional CRO services like NGS, CR (conditionally reprogrammed) cell lines and has a collection of more than 1500 patient derived xenograft (PDX) models covering 40+ cancer types, of which 200+ are special drug resistant and/or genetically altered. More importantly, LIDE specializes in using its proprietary MiniPDX and Kcell Assay Kit to offer Functional Diagnosis - an evolved approach to drug r&d that maximizes budget efficiency and minimizes time to validation. LIDE differentiates itself from other CROs by continually conducting self-funded internal research of its immense tumor bio bank, and working with KOLs in the academic space to vigorously promote the development and application of translational medical research in China. We also adopt the highest international operational standards. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.

Mab Works is committed to bringing novel therapeutics to patients and aspires to become a globally integrated biopharmaceutical company. Their mission is to translate innovative science into value for patients and shareholders.

Since 2003, Medicalsystem Biotechnology Co., Ltd. was first found in Ningbo, today we become one of the leading integrated systems and healthcare service providers of clinical diagnostics in China.Coronavirus Disease 2019 Antibody (IgM/IgG) Combined Test Kit

Membrane Solutions is a rising, creative and world-wide supplier who specializes in a variety of products and solutions in the process of filtration, separation, purification, water & wastewater treatment. Nowadays, our business covers more than 109 countries and regions all over the world, we offer trustworthy products, considerate service as well as consistent innovation in technique. THREE fast growing divisions: Lab Filtration—HPLC and filtration (Syringe Filter, Sample Vials, Membrane Filter etc.) Residential Water Treatment—RO Membrane & Filter, UF Membrane & Filter, Water Purifier & Water Pitcher, Portable Water Treatmetn Devices etc. Industrial Filtration & Water Treatment—Pleated Membrane Cartridge Filter, UF Membrane, MBR Membrane, Integrated Membrane Water Treatment System etc. MS Advantages: Continuously devotion to research & development Mastery for various production craft and technology High quality and value products Globalization of production and customer support Sustainable and stable product supply Close relations with customers Membrane Solutions contribute to the human society by creating innovative technology and value for clean water and environment.

Founded in 2016, MGI has more than 900 employees, nearly half of whom are R&D personnel. MGI operates in 26 countries and regions and has established multiple research and production bases around the world. MGI develops DNA sequencingand related instrumentation.

Nantong Diagnos Biotechnology Co., Ltd. (Diagnos) is a professional POCT(point-of-care testing) manufacturer in China, found in 2006, specialized in researching, developing, manufacturing and distributing advanced medical instruments and in-vitro medical diagnostic products. Diagnos offers quality products in the following specialties: Fertility, Infectious Diseases, Tumor Markers, Cardiac Markers, Substance of Drug Abuse tests and etc.(2019-nCoV) New coronavirus Antibody Test (Colloidal Gold)

NewDEL Biotech is a biotechnology company based in Shenzhen, China, established in 2021. The company focuses on the research and development of new drugs, with a particular emphasis on innovative drugs designed for tumors. NewDEL Biotech utilizes DNA Encoded Library technology to significantly improve the success rate of drug development.

Optical solution provider for life science, industrial laser and other applications

NOVOPROTEIN SCIENTIFIC , the mRNA reagent materials and recombinant proteins supplier from China. Novoprotein provides a one-stop solution of mRNA raw materials and services to support mRNA vaccines research and development. Our products include restriction enzymes, T7 RNA Polymerase, RNase inhibitor, Pyrophosphatase, DNaseI, Nucleotides, Vaccinia Capping Enzyme, mRNA 2´-O-Methyltransferase, Poly(A) Polymerase, RNase R, etc. The manufacturing processes are strictly controlled to ensure the products are animal-free and ampicillin-free. We guarantee the manufacturing and quality control comply with GMP regulation for tracking each step of the manufacturing process, including raw material sourcing. Novoprotein has developed more than ten thousand of recombinant proteins, like cytokines in cell therapy and organoid culture. We have researched and developed 7 technology platforms and 23 core technologies, including protein design and modification, protein production and quality control, protein application and evaluation. Novoprotein provides biomedical Industry customers with services from product development to technological innovation based on a comprehensive technology system and in-house innovative raw materials. James Pan - International Business Development email address: panyanzhi@novoprotein.com.cn

Founded in 2008, Beijing PINS Medical Co., Ltd., is an innovative medical company specializing in R&D, production, and sales of full-range neuromodulation products, including stimulators for deep brain, vagus nerve, spinal cord, and sacral nerve. PINS Medical devotes itself to providing cutting-edge treatments for patients who suffer from neurological disorders such as Parkinson's disease, epilepsy, chronic pain, and uroclepsia. The name of PINS is derived from "Programmable Implanted Neuromodulation Stimulator" and is also an acronym of "patient is no. 1, always." This speaks to the goals of PINS Medical, which are to enhance patient well-being and restore hope, with a focus that goes beyond business to improving society for all citizens. As the incidence of neuropsychiatric disorders continues to rise, placing an increased burden on societies worldwide, PINS Medical, together with research centers, companies, and top academic scientists, will continue to develop the latest cutting-edge therapies and bring them to patients as rapidly and affordably as possible.

Sansure Biotech Inc., now a listed company in China, established in 2008, is an integrated solutions manufacturer and provider with independent innovation of molecular diagnostics and gene technology, has over 10-year experience specialized in diagnostic reagents, nucleic acid diagnostic instruments, complete lab solutions and lab chain services. Sansure solutions for molecular diagnosis are compatible with majority of PCR detection instruments and lab environments based on unique technical platforms “global leading magnetic beads extraction system”, “one of the simplest and fastest one-step DNA/RNA lysis systems”, automated nucleic acid extraction system, POCT devices and real-time PCR instruments. Over 40% of its employees work for R&D and technical service departments, over one hundred of products with global registrations, including infectious diseases, cancer, maternal and child health, blood screening, emerging infectious diseases prevention and control, chronic disease management, etc. "Sansure solutions" have been widely used in nearly 160 countries worldwide, such as France, UK, Germany, Russia, the Philippines, Brazil etc., obtained certificates in over 65 countries, include NMPA China, US FDA EUA，ANVISA, TGA Australia, We are one of the companies with the largest number of overseas certificates. For more information, please contact us at info@sansure.com.cn

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

Mainly supplying the international API market, ScinoPharm has become one of the leading international oncology generic APIs suppliers (in terms of generic APIs supply). In addition to anti-cancer APIs, we have also developed a wide variety of other products including CNS APIs, gastrointestinal APIs, etc.

Established in 1981, Shanghai Kehua Bio-engineering Co., Ltd (KHB) is one of the largest developers, manufacturers and marketers of in vitro diagnostic products in China. In July 2004, we became the first listed company in Shen Zhen Stock Exchange focused on the IVD business. We offer a broad range of products covering three primary business segments: Diagnostic Reagents, Diagnostic Laboratory Instruments, and Evacuated Receptacles.

Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, and manufacture of blood products and plasma-derived medical products.

Shanghai Sunway Biotech is a biopharmaceutical company that develops, manufactures, and commercializes cancer biotherapeutics based on its oncolytic virus platform. The company has been involved in clinical trials and has received approval for oncolytic virus therapy for cancer treatment in China. Shanghai Sunway Biotech aims to provide innovative and effective treatments for cancer patients.

Shengnuo Biotechnology is a high-tech China polypeptide manufacturer,who has over 19 years experience in biotechnology. Their Products involve peptide raw materials,polypeptide drug.

SinoTherapeutics is a specialty pharma focus on the R&D, registration, manufacture and commercialization of complex generic products as well as innovative formulation products (505B2). The company aims to achieve commercialize its product globally, and to provide cost-effective high-quality products to international markets

Snibe is a leading brand of Chemiluminescence immunoassay solution from Shenzhen, China. Also, Snibe is the first company who received FDA cleared on Chemiluminescence immunoassay product in China. With more than 2600 staffs, Snibe has been focusing on Chemiluminescence immunoassay solution for 29 years. At present, Snibe's products have been widely exported to more than 150 countries with 30000 installations globally. Best Quality, Best Service is our target. Snibe would like to be the pioneer in global diagnosis field.

TransGen Biotech Co., Ltd is a researcher and manufacturer of molecular and cellular biology products.

VectorBuilder offer gene delivery technologies. VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside

VivaChek is a leading in-vitro diagnostics company dedicated to enhancing the quality of life by delivering precise and swift disease diagnoses. Our commitment lies in the advancement of healthcare through ongoing research and development in blood glucose monitoring systems, Hemoglobin & Lipid Testing System, FIA Testing System, lateral flow rapid test and Molecular Diagnostics. Our expertise encompasses the development, manufacturing, and distribution of top-tier biosensors and Point-of-Care Testing (POCT) products. Our biosensor offerings span a range of critical parameters, encompassing blood glucose monitoring systems, lactate analyzers, blood ketone meters, and uric acid analyzers. In addition to biosensors, our comprehensive POCT product portfolio includes state-of-the-art PCR, immunoassay, and biochemistry solutions. With a focus on precision, efficiency, and accuracy, our POCT products cater to diverse medical needs, contributing to the rapid and reliable diagnosis of various health conditions.

Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe, efficacious and quality vaccines. Headquartered in China's southwestern city Kunming in Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines. With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, producing efficacious, quality, innovative and affordable products to protect people from the world's deadliest diseases, Walvax's purpose is to help everyone live a healthy life.

West China Hospital, Sichuan University is a healthcare institution that provides tertiary medical services and is the largest single hospital in the world.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

Dongguan Xinyi Biotechnology Co., Ltd. which is established in 2022 in dongguan, is a cosmetics company specializing in production, sales and marketing With first-class production technology and equipment, the company is committed to the research and development . production and sales of high-tech cosmetics, as well as the directional application of traditional Chinese medicine plant raw materials, biological extraction raw materals and functional raw materials. We have cooperated with Australia, Canada and other foreign cooperative manufacturers and professional research institutions to carry out project cooperation, to introduce of advanced management system and cutting-edge science and technology, to develop of domestic first-class, cost-effective personal care products.

The company was founded in December 2005, built a variety of plant and GMP workshop, office space, auxiliary housing, with various types of imports and domestic advanced equipment. The company is a professional R&D, production, sales of rapid in vitro diagnostic reagents of the national high-tech enterprises, Zhejiang Province post-doctoral research station and Huzhou City academician expert workstation set up units. At present, the company's products are widely used in Infectious Disease Rapid Test, Drugs of Abuse Test, Pregnancy & Fertility Tumor Marker Cardiac Marker and other fields, with repeatability and specificity, high sensitivity, easy to operate and other technical characteristics. During the outbreak, the company's new coronavirus testing reagents are widely sold to all corners of the globe. It has made outstanding contributions to the fight against the new coronavirus for all mankind. Since its inception, the company to scientific and technological innovation as the driving force for development, committed to the cause of human health, in order to promote high-tech diagnosis and treatment technology, improve the level and quality of human medical services and efforts. At present, the majority of the company's products have been CE certificated. The company now hopes to expand into the European market. Find local partners in Europe. Better service to the European market.

Zhejiang Medicine Co.,Ltd founded in 1954. currently has nine major subsidiaries and two research units.The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees. Zhejiang Medicine performs the specialized and large-scale production of fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products. The company's leading products, including its synthetic Vitamin E, natural Vitamin E, β-carotene,Lutein, Fish oil(Omega-3) etc.,

Zhuhai Livzon DiagnosticsInc. (hereinafter referred to as “Livzon Diagnostics”) was established in 1989. It is the first high-tech subsidiary of thelisted company, Livzon Pharmaceutical Group (A-shareand H-share listed company),whospecializing in in-vitro diagnosticsin research, developing, manufacturingand marketing of diagnosis productsand automation equipment.Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Colloidal Gold)

More than a decade ago, with the goal of Setting New Standards in Price and Performance, SonoScape specialized itself in ultrasound diagnostic systems and transducers. In 2004 SonoScape released the world's first 15 inch LCD portable color Doppler Ultrasound System. Shortly afterwards SonoScape's product received FDA approval and CE certification and started to be serviced all over the world. Motivated by our goal, we have established a global R&D team with research centers in China and abroad to make the innovative medical technologies accessible and affordable. To reach this goal, SonoScape has continuously introduced new medical products and technologies into the market every year. Consequently SonoScape has expanded into the fields of Endoscopy and Minimally Invasive Surgery to continue providing better healthcare solutions to the world for the purpose of meeting the diagnostic needs of our worldwide customer base. With the Value Proposition of "Unlocking Life's Potential",​ SonoScape has developed and manufactured high quality medical equipment which has benefited millions of people. SonoScape products have become indispensable tools for doctors and clinicians world wide when making critical decisions and reducing their workload. Inspired by the medical needs of the world, we shall continue to dedicate ourselves to delivering meaningful and accessible medical solutions to change lives for the better.

公司的主营业务为特色原料药、医药中间体的研发、生产和销售，以及为客户提供定制加工和研发业务。产品具有手性结构多、研发难度大、技术壁垒高、生产工艺独特等特点。公司是高新技术企业，被认定为“省级高新技术企业研究开发中心”、“省级企业研究院”，公司拥有院士工作站、博士后工作站、博士后创新实践基地等优秀的研发平台，与诸多高校、研究所保持良好的研发合作关系。

自由能计算，化学结构预测；小分子对接；小分子对接计算或者模拟 计算化学，Python ，分子对接，机器学习，数据模型，人工智能，分子对接软件，Amber 软件，Autodock，Schrodinger, MOE，Gaussian 软件，tensorflow, Git, GitHub. 数据分析和建模"，"化学信息学"，"生物信息学"，"量子化学"，"计算化学软件开发"